Xlife Sciences AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF287.25 Mil.
Xlife Sciences AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-31.41 Mil. Xlife Sciences AG's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -10.94%.
The historical rank and industry rank for Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XSWX:XLS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.63 Med: 1.37 Max: 16.91
Current: -12.58
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Xlife Sciences AG was 16.91%. The lowest was -12.63%. And the median was 1.37%.
XSWX:XLS's Earnings Yield (Joel Greenblatt) % is ranked worse than 55.35% of 1337
companies
in the Biotechnology industry
Industry Median: -9.81
vs XSWX:XLS: -12.58
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Xlife Sciences AG's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Xlife Sciences AG (XSWX:XLS) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Xlife Sciences AG Earnings Yield (Joel Greenblatt) % Related Terms
Xlife Sciences AG Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Xlife Sciences AG's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % falls into.
Xlife Sciences AG Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Xlife Sciences AGs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -10.94% mean?
Xlife Sciences AG (XSWX:XLS) has a Earnings Yield (Joel Greenblatt) % of -10.94% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #740 out of 1337 companies in the Biotechnology industry, placing it in the top 55.3%.
Is Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % too high?
Xlife Sciences AG's current Earnings Yield (Joel Greenblatt) % is -10.94%. Based on the distribution chart, Xlife Sciences AG ranks #740 out of 1337 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #740 out of 1337 companies for Earnings Yield (Joel Greenblatt) %. This places Xlife Sciences AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Earnings Yield (Joel Greenblatt) % is -10.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.23, compared to a current price of CHF18.15 — trading 151% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -10.94%. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Earnings Yield (Joel Greenblatt) % is -10.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF18.15 is trading 151% above its estimated GF Value™ of CHF7.23.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Earnings Yield (Joel Greenblatt) %: -10.94%
GF Value™: CHF7.23 vs. price of CHF18.15 (151% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
